Abstract 2086P
Background
Management of opioids use disorder in cancer survivors The morbidity and mortality associated with opioid use disorder is a public health concern in many countries. However, opioids are a cornerstone in the management of cancer pain. The problem of opioid use disorders is an emerging concern in cancer survivors.
Methods
Over 10 months, we evaluated at the Gustave Roussy Pain Management Unit survivors of cancer who were on long-term prescription opioid therapy. A thorough evaluation involving an addiction specialist doctor, a psychologist or a psychiatrist, and the pain team was conducted to answer the following questions: - What is the current painful complaint and are opioids the adequate treatment for it? - Is the patient dependent on prescription opioids and does he/she have prescription opioid misuse? - Does the patient have an addiction to opioids (according to DSMV criteria) A personalized therapeutic project was then proposed for each patient.
Results
All patients accepted the project. Thirteen patients with a prescription opioid use disorder were enrolled for an opioid withdrawal program. Nine patients were misusing step-3 analgesics as defined by the WHO analgesic ladder, including one patient misusing fast-acting fentanyl, and 4 were misusing step-2 analgesics as monotherapy or in combination with another step-2 analgesic. The mean oral morphine equivalent doses were 150 mg daily [40-480 mg]. Nine patients had an opioid prescription renewal for more than 5 years. The fear of the pain rebound was the main obstacle to stopping opioid use. Seven patients could be withdrawn as outpatients six required hospitalizations for withdrawal under strict medical supervision. Five patients were put on Medications for Opioid Use Disorder (MOUD). None of the residual pain complaints warranted an opioid prescription.
Conclusions
Prescription opioids use disorder in cancer survivors requires the intervention of a specialized multidisciplinary team, trained in the identification and treatment of opioid withdrawal, in the handling of MOUD and in the management of chronic pain diseases. Close and regular collaboration with oncologists is necessary, to reconsider the need for prescription opioids in every patient as soon as he/she is in remission.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gustave Roussy Cancer Campus Grand Paris.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06